Cutaneous Lupus Erythematosus Cle clinical trials

Explore recruiting cutaneous lupus erythematosus cle clinical trials.

Recruiting cutaneous lupus erythematosus cle studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cutaneous Lupus Erythematosus Cle trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Blinded, Placebo Controlled, Phase 2a Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants with Cutaneous Lupus Erythematosus (CLE)

Czechia, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care

Spain, Greece, Romania, Poland, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants with Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus and/or Systemic Lupus Erythematosus Having Completed the WILLOW (MS200569_0003) Study Treatment (WILLOW LTE)

Greece, Poland, Romania, Spain, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE)

Italy, Slovakia, Germany, Poland, Hungary, Portugal +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C0251013 - A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF-06823859 IN ADULT PARTICIPANTS WITH ACTIVE CLE OR SLE WITH CUTANEOUS MANIFESTATIONS

Spain, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Cutaneous Lupus Erythematosus Cle trials by city

Cutaneous Lupus Erythematosus Cle in Toronto Cutaneous Lupus Erythematosus Cle in Vancouver Cutaneous Lupus Erythematosus Cle in Montreal Cutaneous Lupus Erythematosus Cle in Calgary Cutaneous Lupus Erythematosus Cle in Edmonton Cutaneous Lupus Erythematosus Cle in Ottawa Cutaneous Lupus Erythematosus Cle in Winnipeg Cutaneous Lupus Erythematosus Cle in Quebec City Cutaneous Lupus Erythematosus Cle in Hamilton Cutaneous Lupus Erythematosus Cle in Kitchener Cutaneous Lupus Erythematosus Cle in London Cutaneous Lupus Erythematosus Cle in Halifax Cutaneous Lupus Erythematosus Cle in New York Cutaneous Lupus Erythematosus Cle in Los Angeles Cutaneous Lupus Erythematosus Cle in Chicago Cutaneous Lupus Erythematosus Cle in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease